mProX™ Human PTGIR Stable Cell Line

Product Information

Target Protein

PTGIR

Target Family

Prostanoid Family

Target Protein Species

Human

Host Cell Type

BEAS-2B; CHO-K1; HEK293

Target Classification

GPCR Cell Lines

Target Research Area

Cancer Research; Cardiovascular Research; Inflammation Research

Related Diseases

Erythroleukemia; Pulmonary Hypertension

Gene ID

5739

UniProt ID

P43119

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PTGIR's cellular function is compromised by genetic flaws, which are probably rare genetic causes of FMD and SCAD. Scientists believe that 0.5% of FMD patients and 0.3% of SCAD patients, respectively, had PTGIR mutations, based on genetic screening of FMD and SCAD cohorts. These estimates need to be refined by larger research, which ought to involve more patients. This discovery and the availability of numerous medications that target this route may aid clinicians in developing customized treatment plans for FMD and SCAD patients. To completely assess the impact of this pathway on the pathophysiology of non-inflammatory stenosis and dissection found in FMD and SCAD arteries, more genetic investigations involving functionally relevant genes are needed. The customized PTGIR stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Gabriel

mProX™ Human PTGIR Stable Cell Line is perfect for my research. Jan 21 2022

chat Verified Customer

chat Sarah

Great service. Aug 03 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Effect of silencing PTGIR

PTGIR and a UC-targeted siRNAs were transfected into BEAS-2B cells. Western blotting was used to compare the impact of PTGIR-1 and pertinent controls on the expression of the variably glycosylated IP receptor.

Ref: Wilson, Sylvia M., et al. "Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of CXCL9 and CXCL10 release." Molecular pharmacology 79.3 (2011): 586-595.

Pubmed: 21173040

DOI: 10.1124/mol.110.069674

Research Highlights

According to this study, patients with SCAD and FMD are more likely to have unusual genetic mutations in the PTGIR gene. This finding raises the possibility that prostacyclin signaling contributes to non-atherosclerotic stenosis and dissection.
Georges, Adrien, et al. "Rare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia." Cardiovascular Research 117.4 (2021): 1154-1165.
Pubmed: 32531060 DOI: 10.1093/cvr/cvaa161

This work demonstrated enhanced PTGIR expression in the swine endometrium throughout the peri-implantation stage and suggested that conceptus-derived factors may be responsible for controlling PTGIR abundance. PGI2 may also encourage the production of proangiogenic genes in the uterine stroma in addition to playing a significant function in the vascular system.
Blitek, Agnieszka, et al. "Prostacyclin receptor (PTGIR) in the porcine endometrium: Regulation of expression and role in luminal epithelial and stromal cells." Theriogenology 84.6 (2015): 969-982.
Pubmed: 26139576 DOI: 10.1016/j.theriogenology.2015.05.034